Analyst Consensus ?
ConsensusBuy39 ratings
Bullish2153.8%
Neutral1743.6%
Bearish12.6%
DuPont de Nemours, Inc. · DD · FY2026 Q3 · Calendar Q4 2026
DuPont raises 2026 outlook after 5% Q3 organic sales growth
The reported Q3 growth, margin expansion and higher full-year outlook support a resilient operating picture, while project delays, inflation, currency and execution risks are meaningful counterweights. This quarter alone does not establish the durability of growth into 2027.
Reported Before market openNYSEBasic Materials
$19.10B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.87
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.84B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+8.7%
Event window
SPY move
+0.6%
Same window
Abnormal move
+8.1%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
DDSPY benchmark
Ask FN2 about DD FY2026 Q3
Transcript, numbers and history already loaded
What drove DD's +8.7% move after FY2026 Q3 earnings?What changed in DD's guidance and outlook in FY2026 Q3?Give me the bull and bear case for DD after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 5% organic sales growth, 90 basis points of margin expansion and 31% adjusted EPS growth for Q3, and raised 2026 guidance to the high end of its prior range. It also said Middle East water-project delays reduced revenue by about $15 million.
Guidance delta
Raised full-year 2026 guidance to the high end of the prior range. The supplied analysis does not include specific revised guidance figures.
Key takeaways
- Q3 organic sales grew 5%, with 90 bps margin expansion and 31% adjusted EPS growth, according to the supplied transcript analysis.
- Management raised full-year 2026 guidance to the high end of the prior range.
- Middle East water-project delays reduced revenue by about $15 million.
- Management cited AI-enabled productivity and faster innovation development; reported analysis says front-end development time fell from three months to five days.
Management priorities
- Continue AI integration in innovation, commercial sales and plant operations.
- Advance the innovation pipeline and target a 50/50 grow-versus-replace mix.
- Pursue share repurchases while maintaining flexibility for acquisitions.
- Execute productivity targets, including 3% net COGS productivity.
Follow DD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$153.46Current
$32.64Low
$56.01Average
$172High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Outperform | Maintain | Oct 15, 2026 |
| JP Morgan | Neutral | Overweight | Downgrade | Oct 9, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 7, 2026 |
| UBS | Buy | Buy | Maintain | Oct 5, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jun 23, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Feb 18, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Feb 12, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 11, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Feb 11, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 11, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Dec 18, 2025 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 29, 2025 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 9, 2022 |
| Vertical Research | Buy | Hold | Upgrade | Nov 3, 2021 |
| Argus Research | Buy | Buy | Maintain | May 14, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | May 11, 2021 |
| DZ Bank | Hold | Sell | Upgrade | Feb 11, 2021 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Jan 28, 2021 |
| Susquehanna | Neutral | Positive | Downgrade | Jan 27, 2021 |
| HSBC | Hold | Buy | Downgrade | Jan 13, 2021 |
| Stephens & Co. | Equal Weight | Overweight | Downgrade | Aug 3, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| CFRA | Buy | Buy | Maintain | May 5, 2020 |
| Gordon Haskett | Buy | Buy | Maintain | Jan 14, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 11, 2019 |
| Citi | Buy | Buy | Maintain | Aug 2, 2019 |
| Nomura | Neutral | Neutral | Maintain | Jun 13, 2019 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jun 10, 2019 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| Bernstein | Outperform | Outperform | Maintain | Sep 1, 2017 |
| CLSA | Underperform | Outperform | Downgrade | Apr 27, 2016 |
| Macquarie | Neutral | Neutral | Maintain | Jul 29, 2015 |
| BGC Financial | Buy | Hold | Upgrade | Sep 19, 2014 |
| PiperJaffray | Neutral | Neutral | Maintain | Jun 5, 2013 |
| Piper Sandler | Neutral | Neutral | Maintain | Jun 5, 2013 |
| Monness, Crespi, Hardt | Neutral | Buy | Downgrade | Oct 24, 2012 |
| Monness Crespi Hardt | Neutral | Buy | Downgrade | Oct 24, 2012 |
| S&P Capital IQ | Buy | Hold | Upgrade | Jul 24, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $153.46. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Arun Viswanathan | $160 | $129.92 | +4.3% | Oct 15, 2026 |
| Barclays | Aleksey Yefremov | $156 | $129.37 | +1.7% | Oct 12, 2026 |
| UBS | Analyst unavailable | $172 | $129.98 | +12.1% | Oct 5, 2026 |
| UBS | Analyst unavailable | $178 | $145.59 | +16.0% | Aug 5, 2026 |
| Goldman Sachs | Joe Ritchie | $53 | $48.26 | -65.5% | Jun 15, 2026 |
| RBC Capital | Analyst unavailable | $60 | $50.54 | -60.9% | May 11, 2026 |
| UBS | Analyst unavailable | $59 | $49.69 | -61.6% | May 6, 2026 |
| RBC Capital | Analyst unavailable | $56 | $46.06 | -63.5% | Apr 24, 2026 |
| Deutsche Bank | Analyst unavailable | $58 | $50.87 | -62.2% | Feb 18, 2026 |
| BMO Capital | Analyst unavailable | $60 | $52.31 | -60.9% | Feb 12, 2026 |
| Morgan Stanley | Analyst unavailable | $52 | $51.47 | -66.1% | Feb 11, 2026 |
| UBS | Analyst unavailable | $56 | $50.32 | -63.5% | Feb 11, 2026 |
| RBC Capital | Arun Viswanathan | $161 | $50.35 | +4.9% | Feb 11, 2026 |
| Mizuho Securities | Analyst unavailable | $52 | $49.43 | -66.1% | Feb 11, 2026 |
| KeyBanc | Aleksey Yefremov | $57 | $50.75 | -62.9% | Feb 11, 2026 |
| Deutsche Bank | David Begleiter | $46 | $43.88 | -70.0% | Jan 23, 2026 |
| RBC Capital | Analyst unavailable | $51 | $43.11 | -66.8% | Jan 21, 2026 |
| KeyBanc | Aleksey Yefremov | $51 | $43.4 | -66.8% | Jan 9, 2026 |
| UBS | Joshua Spector | $49 | $42.89 | -68.1% | Jan 7, 2026 |
| Mizuho Securities | Analyst unavailable | $46 | $40.61 | -70.0% | Dec 18, 2025 |
| RBC Capital | Arun Viswanathan | $48 | $38.7 | -68.7% | Nov 18, 2025 |
| Morgan Stanley | Analyst unavailable | $44 | $40.14 | -71.3% | Nov 10, 2025 |
| KeyBanc | Aleksey Yefremov | $45 | $39.69 | -70.7% | Nov 7, 2025 |
| UBS | Joshua Spector | $44 | $39.13 | -71.3% | Nov 5, 2025 |
| BMO Capital | John McNulty | $50 | $34.38 | -67.4% | Nov 3, 2025 |
| Mizuho Securities | Analyst unavailable | $37.66 | $31.71 | -75.5% | Sep 2, 2025 |
| BMO Capital | John McNulty | $44.77 | $32.18 | -70.8% | Aug 29, 2025 |
| New Street | Analyst unavailable | $44.77 | $32.18 | -70.8% | Aug 29, 2025 |
| UBS | Joshua Spector | $36.4 | $31.29 | -76.3% | Jul 9, 2025 |
| UBS | Joshua Spector | $35.56 | $28.41 | -76.8% | May 21, 2025 |
| RBC Capital | Arun Viswanathan | $37.66 | $27.64 | -75.5% | Apr 24, 2025 |
| RBC Capital | Arun Viswanathan | $42.68 | $32.57 | -72.2% | Aug 5, 2024 |
| BMO Capital | John McNulty | $41.84 | $34.64 | -72.7% | Aug 1, 2024 |
| Wells Fargo | Michael Sison | $43.93 | $35.02 | -71.4% | Aug 1, 2024 |
| Barclays | Duffy Fischer | $35.56 | $33.94 | -76.8% | May 28, 2024 |
| Wells Fargo | Michael Sison | $43.1 | $33.03 | -71.9% | May 24, 2024 |
| BMO Capital | John McNulty | $40.17 | $33.09 | -73.8% | May 23, 2024 |
| Mizuho Securities | John Roberts | $41.84 | $33.17 | -72.7% | May 23, 2024 |
| Jefferies | Laurence Alexander | $42.26 | $32.46 | -72.5% | May 17, 2024 |
| RBC Capital | Arun Viswanathan | $36.4 | $32.53 | -76.3% | May 3, 2024 |
| Bank of America Securities | Steve Byrne | $33.47 | $30.85 | -78.2% | Jan 16, 2024 |
| Citigroup | Analyst unavailable | $37.24 | $32.27 | -75.7% | Feb 8, 2023 |
| Wells Fargo | Analyst unavailable | $35.56 | $32.25 | -76.8% | Feb 8, 2023 |
| Barclays | Analyst unavailable | $33.47 | $32.55 | -78.2% | Feb 8, 2023 |
| Citigroup | Analyst unavailable | $34.31 | $29.14 | -77.6% | Dec 15, 2022 |
| Credit Suisse | Analyst unavailable | $35.98 | $27.56 | -76.6% | May 4, 2022 |
| Mizuho Securities | Analyst unavailable | $40.59 | $27.52 | -73.6% | May 4, 2022 |
| Fermium Research | Frank Mitsch | $32.64 | $28.7 | -78.7% | Apr 18, 2022 |
| Deutsche Bank | David Begleiter | $37.66 | $32.11 | -75.5% | Mar 21, 2022 |
| Morgan Stanley | Vincent Andrews | $38.91 | $34.59 | -74.6% | Jan 11, 2022 |
| UBS | John Roberts CFA | $42.68 | $31.33 | -72.2% | Dec 20, 2021 |
| Vertical Research | Jeffrey Sprague | $39.75 | $32.15 | -74.1% | Nov 2, 2021 |
| J.P. Morgan | Stephen Tusa | $35.56 | $29.12 | -76.8% | Oct 4, 2021 |
| Argus Research | Bill Selesky | $38.91 | $34.28 | -74.6% | May 14, 2021 |
| Goldman Sachs | Robert Koort | $42.68 | $34.11 | -72.2% | May 11, 2021 |
Track every rating change on DD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDuPont de Nemours, Inc. is a global provider of advanced materials and innovative solutions, serving markets across North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are organized into three primary segments: Electronics & Industrial, Mobility & Materials, and Water & Protection. The Electronics & Industrial division focuses on supplying critical materials and advanced systems. This includes products for the advanced printing sector and a comprehensive suite of materials and solutions essential for semiconductor and integrated circuit manufacturing, covering both front-end and back-end processes. It also delivers advanced packaging materials, dielectric and metallization solutions for chip assembly, and specialized silicones for LED packaging and semiconductor uses. Furthermore, the segment provides key chemistries and materials for printed circuit board fabrication, such as laminates, substrates, and various metallization and patterning solutions.…
Historical context
All DD earningsLatest beats and misses
Who reports nextBeat on EPS
- RRXFY2026 Q3 · November 3, 2026+41.1% EPS+11.8% move
- UDRFY2026 Q3 · November 2, 2026+340.8% EPS+0.1% move
- VNOMFY2026 Q3 · November 2, 2026+3.9% EPS-2.6% move
- EQH-PAFY2026 Q3 · November 2, 2026+14.5% EPS— move
- WMBFY2026 Q3 · November 2, 2026+0.2% EPS+3.5% move
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
Get the DD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T18:07:41.771598+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T19:00:45.118536+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T19:00:45.115575+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.